View : 64 Download: 0

Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients

Title
Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients
Authors
Jang, Ji-YongLee, Sang-HakKim, Byung SooSeo, Hong SeogKim, Woo-ShikAhn, YoungkeunLee, Nae-HeeKoh, Kwang KonKang, Tae-SooJo, Sang-HoHong, Bum-KeeBae, Jang-HoYang, Hyoung-MoCha, Kwang SooKim, Bum SooKwak, Choong HwanCho, Deok-KyuKim, UngZo, Joo-HeeKang, Duk-HyunPyun, Wook BumChun, Kook JinNamgung, JuneCha, Tae-JoonJuhn, Jae-HyeonJung, YeiLiJang, Yangsoo
Ewha Authors
편욱범
SCOPUS Author ID
편욱범scopus
Issue Date
2015
Journal Title
KOREAN CIRCULATION JOURNAL
ISSN
1738-5520JCR Link1738-5555JCR Link
Citation
vol. 45, no. 3, pp. 225 - 233
Keywords
ValsartanRosuvastatinDrug therapycombinationControlled clinical trialsrandomizedBlood pressure
Publisher
KOREAN SOC CARDIOLOGY
Indexed
SCIE; SCOPUS; KCI WOS scopus
Abstract
Background and Objectives: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Subjects and Methods: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. Results: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Conclusion: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
DOI
10.4070/kcj.2015.45.3.225
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE